Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad names a new commercial leader while confirming that its previously issued 2026 financial guidance remains unchanged.
Rhea-AI Summary
Myriad Genetics (MYGN) promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, and reaffirmed its full-year 2026 financial guidance.
Sikri previously served as Senior Vice President of Product at Myriad for the past year and has prior molecular diagnostics, oncology and commercial leadership experience at other companies. He will lead the commercial organization following the departure of Chief Commercial Officer Brian Donnelly, who leaves Myriad on September 21, 2026. The company said Sikri’s expertise is expected to support its cancer care continuum focus and profitable growth strategy. Myriad also confirmed that its previously issued 2026 guidance from the July 30, 2026 second-quarter earnings call remains unchanged.
Positive
- Promotion of experienced leader as Executive Vice President - Commercial, effective September 16, 2026
- Full-year 2026 financial guidance explicitly reaffirmed, unchanged from July 30, 2026
Negative
- Departure of Chief Commercial Officer Brian Donnelly effective September 21, 2026
Key Figures
- Executive promotion effective date
- September 16, 2026
- Vishal Sikri promoted to Executive Vice President - Commercial
- Chief Commercial Officer departure
- September 21, 2026
- Brian Donnelly departing Myriad Genetics
Historical Context
-
Reported Q2 revenue decline, reduced 2026 guidance, and suspended prior adjusted EBITDA guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
molecular diagnostics medical
precision medicine medical
financial guidance financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.
Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles at other notable companies.
Brian Donnelly, who has served as Chief Commercial Officer since May of 2025, will be departing Myriad on September 21, 2026.
“I want to thank Brian for his contributions to Myriad,” said Sam Raha, President and CEO of Myriad Genetics. “We are excited to have Vishal lead our commercial organization. His deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of our cancer care continuum focus and profitable growth strategy going forward.”
“I’m energized to lead the commercial organization at this important stage for Myriad,” said Mr. Sikri. “I look forward to partnering with Sam and the executive leadership team to advance Myriad’s mission, serve more patients and healthcare providers, and create increased value for shareholders.”
The company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call on July 30, 2026.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call, and Mr. Sikri’s deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of the company’s Cancer Care Continuum focus and profitable growth strategy going forward. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Andria Rosell (385) 202-3510 PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Brian Donnelly depart from Myriad Genetics and what was his role?
Brian Donnelly, who has served as Chief Commercial Officer since May 2025, will depart Myriad Genetics on September 21, 2026.
What prior role did Vishal Sikri hold at Myriad before becoming Executive Vice President - Commercial?
Before his promotion, Vishal Sikri served as Senior Vice President of Product at Myriad for the past year.
What does Myriad say about the strategic focus linked to Sikri’s new role?
The company said Sikri’s domain knowledge and track record of driving growth and operational excellence are expected to help execute Myriad’s cancer care continuum focus and pursue a profitable growth strategy.
What period does the reaffirmed financial guidance cover and when was it originally issued?
The reaffirmed guidance covers the full-year 2026 and was originally announced during Myriad’s second quarter 2026 earnings call on July 30, 2026.